Literature DB >> 17375894

Primary cardiac lymphoma and complete atrio-ventricular block: case report and review of the literature.

Virginie Montiel1, Nicolas Maziers, Thierry Dereme.   

Abstract

Primary cardiac lymphoma (PCL) is a rare and extremely aggressive malignancy, which can express itself by damaging the cardiac conduction system (complete atrio-ventricular block), the myocardium and the pericardium. Histology confirms the diagnosis. Chances of survival depend on early diagnosis and treatment. We present the case of a female patient admitted for severe deterioration of her general state of health who had a complete atrio-ventricular block caused by a tumour of the atrial septum, a B-cell lymphoma stage I. The diagnosis was suggested by combined PET/CT imaging and confirmed by histology of a cardiac biopsy. Her general clinical condition, including the cardiac parameters, significantly improved following chemotherapy induction.

Entities:  

Mesh:

Year:  2007        PMID: 17375894     DOI: 10.2143/AC.62.1.2019372

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  4 in total

1.  Can stem blood cell transplantation be an adjuvant treatment for primary cardiac lymphoma?

Authors:  Reinaldo B Bestetti; Carlos E Miguel
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

2.  [ECG changes in primary neurological disorders, systemic diseases and primary cardioymopathies].

Authors:  E Kaya; C Fischer; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-05-09

3.  Primary cardiac lymphoma: computed tomography and magnetic resonance imaging features.

Authors:  Daisuke Utsunomiya; Kazuo Awai; Joji Urata; Touitsu Hirayama; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2009-07-22       Impact factor: 2.374

4.  A case of complete atrioventricular block associated with primary cardiac lymphoma reversed without cardiac pacemaker implantation.

Authors:  Bowen Hu; Jian Zhao; Xin Liang; Changzhen Ren; Na Li; Chun Liang
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.